trending Market Intelligence /marketintelligence/en/news-insights/trending/D8CuJM3m-zB4KxH9RjZGNQ2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Mo. Supreme Court denies J&J request to delay talc-related cancer trials

Blog

Global M&A Infographic Q1 2021

Blog

Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge

Blog

COVID-19 Impact & Recovery: Private Equity

COVID-19 Impact & Recovery: Corporates


Mo. Supreme Court denies J&J request to delay talc-related cancer trials

The Missouri Supreme Court denied Johnson & Johnson and its baby powder talc supplier's requests to delay upcoming trials relating to the company's talc-based products.

The trials are over allegations that the company's talc-based products led to the development of ovarian cancer in some women. The court's ruling allows the next trial to proceed on Feb. 6 in St. Louis.

Attorneys for Johnson & Johnson and Imerys Talc America had previously requested the court to deny the jurisdiction of the 22nd Circuit Court in St. Louis to hear the cases, arguing that most of the plaintiffs with pending claims are not Missouri residents. However, the court has rejected their motions.

An appeals court had also denied the motions earlier in January.

In 2016, St. Louis juries returned three separate verdicts of $70 million, $72 million and $55 million for cancer victims who sued Johnson & Johnson. The cases claim that several scientific studies found the link between ovarian cancer and genital use of talc-containing products manufactured and marketed by Johnson & Johnson, including Johnson's Baby Powder and Shower to Shower.

Attorneys for the plaintiffs claim that the companies knew about the dangers of talcum powder but suppressed and dismissed the research and refused to provide warning labels on talc-containing products.